CymaBay Therapeutics, Inc. (NASDAQ:CBAY) Files An 8-K Submission of Matters to a Vote of Security Holders

Item5.07. Submission of Matters to a Vote of Security Holders.

On June1, 2017, CymaBay Therapeutics, Inc.
(CymaBay) held its 2017 Annual Meeting
of Stockholders (the Annual Meeting).
Set forth below is a brief description of each matter considered
and voted upon at the Annual Meeting, together with the final
tally of the number of votes cast for, against or withheld, as
well as the number of abstentions and broker non-votes as to each
such matter, including a separate tabulation with respect to each
of the nine directors. A more complete description of each matter
is set forth in CymaBays definitive proxy statement for the
Annual Meeting filed with the Securities and Exchange Commission
on April19, 2017 (the Proxy Statement).

Proposal 1: Election of Directors.

CymaBays Stockholders elected each of the nine directors proposed
by CymaBay for election, to serve until the 2018 annual meeting
of stockholders, and until their successors are elected and have
qualified, or until their earlier death, resignation or removal.
The tabulation of votes on this matter was as follows:

There were 15,000,579 broker non-votes for this proposal.

Proposal 2: Ratification of Selection of Independent
Registered Public Accounting Firm

CymaBays Stockholders ratified the appointment of Ernst Young LLP
as CymaBays independent registered public accounting firm for the
fiscal year ending December31, 2017. The tabulation of votes on
this matter was as follows:

About CymaBay Therapeutics, Inc. (NASDAQ:CBAY)

CymaBay Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies to treat metabolic diseases, including serious rare and orphan diseases. The Company’s product candidates include Arhalofenate, MBX-8025 and MBX-2982. Arhalofenate is used to treat gout. MBX-8025 is a selective agonist for the peroxisome proliferator-activated receptor delta (PPARd). The Company has completed over five Phase I clinical studies and a Phase II clinical study for MBX-8025. MBX-2982 is an oral, G-protein coupled receptor agonist being evaluated as a therapeutic agent for patients with Type 2 diabetes (T2DM), with a dual mechanism, including direct effects and indirect effects mediated by gastrointestinal hormones known as incretins on glucose-dependent insulin secretion, as well as potentially beneficial effects on islet health. The Company has completed over four Phase I clinical studies and a Phase II clinical study for MBX-2982.